NoaLavi et al. 2013 published in the journal ThrombosisResearch on the treatment of pregnancy in women with myeloproliferative neoplasms. Pregnancy itself is in a hypercoagulable state and myeloproliferative neoplasms provide a thrombotic environment that increases the risk of placental thrombosis, fetal growth retardation or miscarriage, maternal venous thrombotic events, especially deep thrombosis (DVT) and pulmonary embolism. 461 pregnancies with ET were studied and 50-70% of ETs were delivered successfully. Fetal miscarriage was significantly increased, with early pregnancy miscarriage occurring in about 25C40%, placental abruption in 3.6C4.5%, intrauterine growth retardation (IUGR) in 3-5%, and preterm delivery in 8C12.8%. Maternal thrombosis and hemorrhage are uncommon, with a cumulative maternal thromboembolic event rate of 5% and hemorrhage 3%.